In the context of the bilateral agreement signed between Argentina and the Republic of India on the use of nuclear energy for peaceful purposes, INVAP is providing India with a Radioisotope Production Facility, called RPF India to produce molybdenum 99 (Mo-99) for medical applications.
The facility uses low-enriched uranium (LEU) through a process developed by the Argentine National Commission of Atomic Energy (CNEA, in Spanish).
The project of the turnkey plant includes the design, manufacture, supply, installation and implementation of a Mo-99 production facility with a capacity of 300 Ci per week (precalibrated for six days) to be built at the Bhabha Atomic Research Centre (BARC), in Mumbai, for the Board of Radiation and Isotope Technology (BRIT) dependent on the Department of Atomic Energy (DAE) of India.
The agreement includes staff technical training in Argentina and India to operate the future plant. INVAP will also supply the materials, consumables and spare parts required for the implementation tests and the beginning of the routine production.
The project involves the development of the technological systems, that is, the components and equipment required for the radiochemical process as well as auxiliary facilities and services related to this process, such as electrical panels, ventilation and safety systems, preparation and quality control laboratories, process cells, operation area, irradiated target reception and radioactive waste disposal, among others.
The facility, which includes offices, laboratories and conventional auxiliary service areas, has been built by BRIT taking into account INVAP’s specifications and recommendations.